News

Fierce Biotech1h

Stealth Bio submits third FDA application for rare disease candidate

After an FDA rejection in May, Stealth BioTherapeutics has resubmitted a new drug application for its investigational ...
Fierce Biotech2h

Boehringer pens $327M pact with Palatin to develop new therapies for diabetic retinopathy

Palatin has a research program in DR, and more specifically, in diabetic macular edema (DME), a complication of DR that ...
Fierce Biotech1h

Baxter’s Novum IQ corrections grow in scope to include syringe pumps

Baxter’s efforts this summer to correct high-risk issues with its infusion pumps has gotten more complicated.  | Last month ...
Fierce Biotech3h

Merck KGaA swoops into Skyhawk neurological disease pact worth up to $2B

Merck KGaA has swooped into a neurological-focused pact with RNA biotech Skyhawk Therapeutics that could top out at $2 ...
Fierce Biotech5h

Reunion’s psychedelic prodrug reduces postpartum depression symptoms in ph. 2 study

Reunion Neuroscience’s psychedelic has reduced the symptoms of postpartum depression in a phase 2 study, setting up the ...
Fierce Biotech5h

Pfizer’s SCD drug fails ph. 3 study in latest blow to Global Blood Therapeutics' legacy

Pfizer set about evaluating inclacumab in pair of phase 3 studies, dubbed Thrive. The Big Pharma terminated one of those ...
Fierce Biotech1h

Neurizon becomes second biotech hit with FDA delay for ALS candidate

Yet another biotech is facing a delay from the Food and Drug Administration as the agency reels from intense staffing cuts. | Yet another biotech is facing a delay from the Food and Drug ...